NICE says no to AZ's Lynparza

The British group has deemed AZ's ovarian cancer drug too expensive. 

By Nicole Gray • June 2, 2015

CEO of cancer vax rising star Bavarian Nordic: We are not for sale

The small Danish biopharma wants to blaze its own trail despite some high-profile deals.

By Nicole Gray • May 27, 2015

Trouble for AZ as Amgen quits psoriasis blockbuster hopeful collab over suicide risk

The biotech fears that brodalumab's label could prove too restrictive. And it could put the hurt on AZ's revenues.

By Nicole Gray • May 26, 2015

Word on the street: A massive Pfizer deal is coming

The speculation is that potential targets include AstraZeneca, Glaxo, Shire, and Mylan.

By Nicole Gray • May 22, 2015

Valeant chief latest pharma CEO to question M&A mania, calls it a 'bit of a bubble'

Michael Pearson says that his company's approach to acqusitions is "less cyclical...than the industry as a whole."

By Nicole Gray • May 22, 2015

CVS to buy nursing home pharmacy Omnicare for $12.7 billion

The consequent spike in pharmaceutical services for older Americans will only bolster CVS' position as the largest retail Rx dispenser in the U.S.

By Sy Mukherjee • May 21, 2015

Valeant reportedly in acquisition talks with big Egyptian pharma

If completed, acquisition of Amoun would be one of the largest acquisitions of a pharmaceutical company in the Middle East.

By Nicole Gray • May 21, 2015

Endo to scoop up rival Par Pharma for $8B in bid to expand generics portfolio

The company also cites operational and tax savings as rationales for the deal.

By Nicole Gray • May 19, 2015

Perrigo CEO changes tune, would consider Mylan merger—at right price

Joseph Papa is playing hardball to get a high bid.

By Nicole Gray • May 19, 2015

One more potential Teva-related challenge for Mylan's shareholders: A huge tax bill

Shareholders could be forced to foot a big bill for short-term capital gain taxes if a deal closes before the end of February 2016.

By Nicole Gray • May 15, 2015

Sanofi moving forward on Celiac disease immunotherapy development

The French pharma giant has a collaborative partnership with Selecta Biosciences.

By Nicole Gray • May 14, 2015

Glaxo CEO skeptical about pharma's M&A frenzy

Andrew Witty feels the industry's "deal rush" is fueled by cheap money, rather than the true value of acquisitions.

By Nicole Gray • May 13, 2015

HIV cure, not just treatment, is goal of Glaxo-UNC partnership

Academic and pharmaceutical researchers will work side-by-side on potential therapies to cure the virus.

By Nicole Gray • May 12, 2015

Mylan chairman thinks Teva a bad cultural fit, would consider buying it anyway

There's some mixed messaging coming from Robert Coury.

By Sy Mukherjee • May 11, 2015

M&A mayhem: Q1 biopharma deal values surpass 2014's total

There's been more than $166 billion in life sciences deals so far this year.

By Nicole Gray • May 8, 2015

Alexion to buy Synageva BioPharma in $8.4B rare disease megadeal

The deal values Synageva at more than double its Tuesday closing price.

By Sy Mukherjee • May 6, 2015

Bayer buys rights to Isis anti-clotting drug in $155M deal

The company's goal is to bolster its cardiovascular (CVD) franchise, which includes Xarelto, a novel oral anticoagulant.

By Nicole Gray • May 5, 2015

Pfizer emerges as mystery bidder for rare disease firm Swedish Orphan

Biogen and Investor AB were also considered contenders for acquisition of Swedish Orphan Biovitrum AB, also known as Sobi. 

By Nicole Gray • May 1, 2015

Perrigo rejects Mylan's third takeover offer

The company contends that when everything is factored in, Mylan's last two offers have been lower than the original $205 per-share offer.​

By Nicole Gray • April 30, 2015

Rare disease firm Swedish Orphan flies on mystery takeover offer

But the company's staying mum on who it is.

By Nicole Gray • April 27, 2015

A tale of 2 takeover bids: Teva-Mylan-Perrigo M&A drama goes hostile

Teva is pursuing Mylan while Mylan pursues Perrigo, and no one seems particularly interested in striking a deal.

By Nicole Gray • April 27, 2015

Novartis chief: We're actively looking for $2-$5 billion acquisitions

Which companies might get snatched up by the pharma giant?

By Nicole Gray • April 24, 2015

What biopharma needs to know about CAR-T cancer therapies

Pharmaceutical companies, government agencies, and high profile advocacy groups are developing collaborative alliances to unlock the potent therapeutic potential of CAR-T.

By Nicole Gray • April 24, 2015

Abbott's Mylan deal paying off big as M&A speculation sends shares soaring

Mylan shares have climbed more than 28% in the last three months.

By Nicole Gray • April 23, 2015

Bernstein analyst to Gilead: 'Pull the trigger' and buy Vertex

Geoffrey Porges believes that the "inevitable decline" of Gilead's HIV and hepatitis C franchises can be offset with the right acquisition. 

By Nicole Gray • April 22, 2015